FMP
Zynerba Pharmaceuticals, Inc.
ZYNE
NASDAQ
Inactive Equity
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
1.3 USD
0.03 (2.31%)
About
ceo
Mr. Armando Anido MBA
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.zynerba.com
exchange
NASDAQ
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
CIK
0001621443
ISIN
US98986X1090
CUSIP
98986X109
Address
80 West Lancaster Avenue
Phone
484 581 7505
Country
US
Employee
25
IPO Date
Aug 5, 2015
Key Executives
